HIKAL
Chemicals & Related Products · India · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Great Eastern Chambers Sector 11 Cbd Bel...Phone Number
+91 2230973100Website
www.hikal.comRevenue
$214.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About HIKAL
Hikal, headquartered in Mumbai, India, specializes in Custom Synthesis and Contract Manufacturing of Agrochemicals, Intermediates, and Specialty Chemicals.Explore more
HIKAL Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HIKAL your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
HIKAL, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if HIKAL is spiking on competitors!
Check if HIKAL has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at HIKAL
Earning: See what the market has to say on HIKAL recently announced quarterly report
Product Launch: Get notified when HIKAL launches new products
Click to see if HIKAL had a recent Job posting/layoffs
Funding: Get notified immidiatlly once HIKAL has new funding data
Recommended Actions
Find VP level buyers at HIKAL
Find more new buyers
Company Profile Activity
Activity Insights
HIKAL is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HIKAL is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HIKAL.
HIKAL Tech Stack
A closer look at the technologies used by HIKAL
Most Recent Scoops
Pain Point
reported an adverse impact of approximately INR 7 to 8 crore on EBITDA in Q1 FY27 due to increased raw material and energy prices in its Crop Protection division, with the company expecting oil prices to begin declining and normalizing by the end of Q2, though geopolitical volatility creates continued uncertainty.
Earnings, Finance, Risk
Pain Point
HIKAL is experiencing continued pricing pressure in its Crop Protection business due to excess supply from China, limiting price increase opportunities, while geopolitical tensions are driving up raw material and energy costs, with only partial pass-through available on certain contracts as end product prices to farmers have not materially increased.
Pain Point, Finance, Pricing, Risk
Earnings
HIKAL has indicated that upon receiving final US FDA clearance, its full-year growth guidance of 14% to 16% for FY27 is expected to accelerate further in FY28, with the pharmaceutical division projected to achieve a CAGR of 18% to 19% going forward, potentially faster if pending NCE filings receive approval.
Forecasting, Pharmaceuticals
Earnings
reported capital expenditure of approximately INR 45 crore for Q1 FY27, focused on debottlenecking, regulatory upgrades, and building new capacities, with growth initiatives largely financed through internal accruals. As of June 30, 2026, the company's debt-equity ratio stood at 0.53, improved from 0.56 in the prior March quarter.
Spending/Investment, Capacity Planning, Finance, Financing & Debt
Earnings
Forecasting
HIKAL News & Media
Hikal Brings Digital Transformation to Historic Zilla Parishad School in Alibaug
Hikal, a trusted partner to global life sciences companies, has further demonstrated its commitment to rural education and sustainable development with a transformative initiative at the historic Zilla Parishad Marathi School in Zirad, Alibaug, which has been standing for 130 years. In collaboration with Utkarsh Global Foundation, this effort forms a key part of Hikal’s Machine Maker - Latest Manufacturing News | Indian Manufacturing News - Latest Manufacturing News | Indian Manufacturing News -Dispute between two promoters not to impact corporate performance: Hikal
Pharmaceuticals and crop protection firm Hikal Ltd on Thursday refuted allegations by proxy advisory firm InGovern Research Services that the battle between its two promoters is impacting corporate performance. Hikal is in the midst of a battle between two promoter groups -- the Hiremaths who own 34.84 per cent stake and Baba N Kalyani (BNK)-led side that holds 34.01 per cent of the company. Minority shareholders own 31.15 per cent. InGovern in a note toWarring sibling promoters put Hikal's future at stake, says InGovern
Calls for change in management, board to protect minority shareholders' interestFight over control of Hikal: Hiremath, family move HC against Baba Kalyani
Hikal said it did not expect any financial implications arising due to compensation, penalty, etc, due to the suit
Read more news
Top Chemicals & Related Products Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding HIKAL
Sign Up For FreeTo access detailed company insights
Hikal, headquartered in Mumbai, India, specializes in Custom Synthesis and Contract Manufacturing of Agrochemicals, Intermediates, and Specialty Chemicals.... Read More
